false
OasisLMS
Catalog
SCCM Resource Library
Four-Factor PCCs Are Preferred for Intracerebral H ...
Four-Factor PCCs Are Preferred for Intracerebral Hemorrhage Management
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The presentation discussed strategies for managing intracerebral hemorrhage (ICH) with a focus on the four-factor prothrombin complex concentrate (PCC) and its comparison to andexanet alpha, a drug specifically indicated for reversing factor Xa inhibitors. The speaker clarified that the debate is not between two reversal agents but between different management strategies for ICH. While andexanet alpha pharmacologically reverses the anticoagulation effect and is FDA approved, challenges persist such as availability and cost. PCCs, on the other hand, provide clotting factors without reversing the effect of the drug directly, yet are more widely available and cost-effective. The discussion highlighted the importance of preventative measures and common data elements to standardize reporting and improve patient outcomes, emphasizing that current data is inconsistent, retrospective, and varied in endpoints, which complicates decision-making. Additionally, the speaker stressed the necessity for individualized treatments and the timely administration of interventions.
Asset Caption
45-Minute Session | Pro/Con Debate: Flip It and Reverse It: ICH Management
Meta Tag
Content Type
Presentation
Membership Level
Professional
Membership Level
Select
Year
2024
Keywords
intracerebral hemorrhage
prothrombin complex concentrate
andexanet alpha
factor Xa inhibitors
preventative measures
individualized treatments
×
Please select your language
1
English